Gossamer Bio, Inc. Company Analysis & Research
Gossamer Bio is a late-stage clinical biopharmaceutical company focused on developing seralutinib for rare pulmonary diseases, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company recently announced Phase 3 PROSERA trial results that narrowly missed the primary efficacy endpoint but showed benefit in key subgroups.
The company is pursuing a focused development strategy with seralutinib as its lead candidate, jointly developed with the Chiesi Group. Gossamer maintains solid cash position (~$180M) but faces regulatory uncertainty following the PROSERA trial outcome, with plans to engage FDA on path forward. The company also has a pipeline including GB004 (IBD), GB001 (eosinophilic asthma), and GB1275 (oncology).
Company Overview
Headquarters: San Diego, US. Revenue: $44.1M. Market Cap: $561M. Ticker: GOSS (NASDAQ).
Industry
Biopharmaceuticals - Rare/Orphan Pulmonary Diseases
Cyborg Score: 5/10 — Mixed
High-risk clinical-stage biotech with potential upside if FDA approves seralutinib despite missed primary endpoint, but significant downside if regulatory path narrows.
Gossamer Bio exhibits mixed fundamentals: solid liquidity and cash position supporting 1-2 years of runway, but faces critical near-term regulatory hurdle after missing primary PROSERA endpoint. Strong analyst coverage and recent Barclays overweight rating provide some confidence, but binary trial outcome creates significant downside risk. Revenue generation (est. ~$44M) remains pre-commercial.
Key Strategic Insights for Gossamer Bio, Inc.
- February 2026 PROSERA Phase 3 results missed primary endpoint (p=0.0320 vs. α=0.025 threshold) but showed +20m benefit in intermediate/high-risk subgroup (p=0.0207)
- Strong regional variability with North America showing +25.9m improvement; enrollment paused in SERANATA study pending FDA discussions
- Solid balance sheet with ~$180M cash and $200M convertible notes maturing 2027; current market cap ~$561M based on Oct 2025 data
- Analyst price targets range $9-10 (341% upside from $2.15 current); Barclays initiated Overweight with $9 PT in early February 2026
Recent Developments
- (February 2026) PROSERA Phase 3 topline results announced with 13.3m placebo-adjusted 6MWD improvement, missing primary alpha threshold
- (February 2026) Company pausing SERANATA enrollment to evaluate regional placebo response discrepancies and plan FDA engagement
- (February 2026) Barclays initiated coverage with Overweight rating and $9 price target
- (January 2026) Non-qualified stock option grants approved for non-executive employees under Nasdaq Rule 5635
Competitors & Competitive Landscape
- Gilead Sciences/GSK/Bayer — Established PAH therapies with proven efficacy and market share
- United Therapeutics — Dominant PAH player with diversified prostanoid portfolio
- Various biotech — Rare disease-focused biotech competitors in immunology/inflammation space
Gossamer Bio competes in rare/orphan pulmonary disease space against established PAH players (Actelion/Janssen, United Therapeutics, Gilead) and emerging biotech competitors. The company's focused pipeline approach (seralutinib as lead) contrasts with competitors' broader PAH portfolios. Limited direct competition in PH-ILD segment creates differentiation opportunity, though PROSERA trial setback weakens near-term competitive positioning versus established therapies.
More Company Research
Manazel Holding Company K.P.S.C. Nerdy, Inc. Kewal Kiran Clothing Limited Saudi Steel Pipes Company CytomX Therapeutics, Inc. NGL Energy Partners LP Jamf Holding Corp Netcompany Group A/S Griffon Corporation Ricoh Company, Ltd. Cerebras Systems Inc. Uni-President Enterprises Corporation Fujikura Ltd. Deutsche Telekom AG Liberty TripAdvisor Holdings, Inc.Full Company Research Reports
Looking for a more in-depth analysis of Gossamer Bio, Inc.? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, analyst debate audio, and saved-company audio playlists.